"Angiopoietin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.
| Descriptor ID |
D042702
|
| MeSH Number(s) |
D12.644.276.100.100.200 D12.776.467.100.100.200 D23.529.100.100.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Angiopoietin-2".
Below are MeSH descriptors whose meaning is more specific than "Angiopoietin-2".
This graph shows the total number of publications written about "Angiopoietin-2" by people in this website by year, and whether "Angiopoietin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiopoietin-2" by people in Profiles.
-
Catalpol Protects Against Retinal Ischemia Through Antioxidation, Anti-Ischemia, Downregulation of ?-Catenin, VEGF, and Angiopoietin-2: In Vitro and In Vivo Studies. Int J Mol Sci. 2025 Apr 24; 26(9).
-
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025 May; 263(5):1239-1247.
-
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
-
Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis. Clin Res Hepatol Gastroenterol. 2022 05; 46(5):101909.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
-
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
-
Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated With Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2017 Feb 01; 74(2):134-141.
-
Variants in angiopoietin-2 (ANGPT2) contribute to variation in nocturnal oxyhaemoglobin saturation level. Hum Mol Genet. 2016 12 01; 25(23):5244-5253.
-
Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. Circulation. 2016 Jul 12; 134(2):141-52.
-
Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep. 2015 Feb 24; 10(7):1066-81.